A detailed history of Susquehanna International Group, LLP transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 541,620 shares of BLUE stock, worth $173,318. This represents 0.0% of its overall portfolio holdings.

Number of Shares
541,620
Previous 901,933 39.95%
Holding current value
$173,318
Previous $883,000 68.18%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.47 - $1.35 $169,347 - $486,422
-360,313 Reduced 39.95%
541,620 $281,000
Q2 2024

Aug 15, 2024

SELL
$0.85 - $1.26 $366,661 - $543,521
-431,366 Reduced 32.35%
901,933 $883,000
Q1 2024

May 07, 2024

SELL
$0.91 - $1.75 $137,016 - $263,494
-150,568 Reduced 10.15%
1,333,299 $1.71 Million
Q4 2023

Feb 14, 2024

BUY
$1.32 - $4.83 $1.18 Million - $4.3 Million
890,521 Added 150.08%
1,483,867 $2.05 Million
Q3 2023

Nov 14, 2023

BUY
$3.02 - $4.05 $242,240 - $324,858
80,212 Added 15.63%
593,346 $1.8 Million
Q2 2023

Aug 11, 2023

SELL
$2.79 - $5.03 $2.16 Million - $3.9 Million
-775,685 Reduced 60.19%
513,134 $1.69 Million
Q1 2023

May 16, 2023

BUY
$3.14 - $8.22 $2.64 Million - $6.92 Million
841,766 Added 188.29%
1,288,819 $4.1 Million
Q4 2022

Feb 14, 2023

SELL
$5.77 - $8.49 $1.72 Million - $2.54 Million
-298,894 Reduced 40.07%
447,053 $3.09 Million
Q3 2022

Nov 14, 2022

BUY
$3.75 - $7.39 $392,782 - $774,043
104,742 Added 16.34%
745,947 $4.72 Million
Q2 2022

Aug 15, 2022

BUY
$2.94 - $5.23 $901,665 - $1.6 Million
306,689 Added 91.68%
641,205 $2.66 Million
Q1 2022

May 16, 2022

SELL
$4.07 - $10.6 $132,238 - $344,404
-32,491 Reduced 8.85%
334,516 $1.62 Million
Q4 2021

Feb 14, 2022

BUY
$8.96 - $16.31 $492,665 - $896,805
54,985 Added 17.62%
367,007 $3.67 Million
Q3 2021

Nov 15, 2021

SELL
$11.24 - $21.0 $493,256 - $921,564
-43,884 Reduced 12.33%
312,022 $5.96 Million
Q2 2021

Aug 11, 2021

SELL
$18.04 - $22.09 $3.22 Million - $3.94 Million
-178,317 Reduced 33.38%
355,906 $11.4 Million
Q1 2021

May 17, 2021

BUY
$16.59 - $33.89 $5.54 Million - $11.3 Million
334,074 Added 166.91%
534,223 $16.1 Million
Q4 2020

Feb 16, 2021

BUY
$27.5 - $37.92 $1.64 Million - $2.27 Million
59,787 Added 42.59%
200,149 $8.66 Million
Q3 2020

Nov 16, 2020

SELL
$34.44 - $43.75 $279,446 - $354,987
-8,114 Reduced 5.46%
140,362 $7.57 Million
Q2 2020

Aug 14, 2020

BUY
$27.12 - $45.97 $150,760 - $255,547
5,559 Added 3.89%
148,476 $9.06 Million
Q1 2020

May 15, 2020

SELL
$26.16 - $63.5 $1.28 Million - $3.11 Million
-48,988 Reduced 25.53%
142,917 $6.57 Million
Q4 2019

Feb 14, 2020

BUY
$46.96 - $61.67 $134,305 - $176,376
2,860 Added 1.51%
191,905 $16.8 Million
Q3 2019

Nov 14, 2019

SELL
$59.47 - $93.1 $1.24 Million - $1.94 Million
-20,836 Reduced 9.93%
189,045 $17.4 Million
Q2 2019

Aug 16, 2019

BUY
$75.84 - $105.21 $301,160 - $417,788
3,971 Added 1.93%
209,881 $26.7 Million
Q2 2019

Aug 14, 2019

BUY
$75.84 - $105.21 $11.8 Million - $16.3 Million
155,017 Added 304.59%
205,910 $26.2 Million
Q1 2019

May 15, 2019

SELL
$64.44 - $104.11 $9.94 Million - $16.1 Million
-154,208 Reduced 75.19%
50,893 $8.01 Million
Q4 2018

Feb 14, 2019

BUY
$59.1 - $93.26 $993,589 - $1.57 Million
16,812 Added 8.93%
205,101 $20.3 Million
Q3 2018

Nov 14, 2018

SELL
$88.86 - $117.49 $13.3 Million - $17.5 Million
-149,346 Reduced 44.23%
188,289 $27.5 Million
Q2 2018

Aug 14, 2018

BUY
$99.64 - $127.59 $29.3 Million - $37.5 Million
293,985 Added 673.51%
337,635 $53 Million
Q1 2018

May 15, 2018

SELL
$105.8 - $150.94 $4.89 Million - $6.98 Million
-46,222 Reduced 51.43%
43,650 $7.45 Million
Q4 2017

Feb 14, 2018

SELL
$81.25 - $130.7 $6.1 Million - $9.81 Million
-75,062 Reduced 45.51%
89,872 $16 Million
Q3 2017

Nov 14, 2017

BUY
$57.74 - $91.42 $9.52 Million - $15.1 Million
164,934
164,934 $22.7 Million

Others Institutions Holding BLUE

About bluebird bio, Inc.


  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $24.7M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.